Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Get Free Report) shares dropped 4.8% on Tuesday. The stock traded as low as $1.76 and last traded at $1.8650. Approximately 69,189 shares were traded during mid-day trading, a decline of 70% from the average session volume of 233,537 shares. The stock had previously closed at $1.96.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on ATHE shares. Lake Street Capital started coverage on shares of Alterity Therapeutics in a research report on Tuesday, September 15th. They set a “buy” rating and a $10.00 target price on the stock. Weiss Ratings cut shares of Alterity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Craig Hallum set a $2.00 price target on shares of Alterity Therapeutics in a report on Tuesday, August 11th. Finally, UBS Group set a $12.00 price target on shares of Alterity Therapeutics in a report on Tuesday, August 11th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.00.
Read Our Latest Research Report on Alterity Therapeutics
Alterity Therapeutics Stock Down 2.6%
The stock has a 50-day moving average of $2.83 and a 200 day moving average of $3.88.
Alterity Therapeutics (NASDAQ:ATHE – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported ($0.28) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million for the quarter. Analysts anticipate that Alterity Therapeutics Limited – Sponsored ADR will post -0.12 EPS for the current year.
Hedge Funds Weigh In On Alterity Therapeutics
A hedge fund recently raised its stake in Alterity Therapeutics stock. Greenleaf Trust boosted its holdings in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Free Report) by 93.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 62,000 shares of the company’s stock after acquiring an additional 30,000 shares during the period. Greenleaf Trust owned 0.70% of Alterity Therapeutics worth $333,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 2.14% of the company’s stock.
Alterity Therapeutics Company Profile
Alterity Therapeutics is an Australian clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on conditions associated with abnormal protein accumulation and disrupted iron balance in the brain, including multiple system atrophy (MSA) and Parkinson’s disease. The company’s lead candidate, ATH434, is an investigational small-molecule therapy being studied for MSA. Alterity is evaluating the treatment in clinical trials; it is not an approved medicine.
Recommended Stories
- Five stocks we like better than Alterity Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
